Objective: Previous studies examining seizures in patients with 22q11.2 deletion syndrome (22q11.2DS) have focused primarily on children and adolescents. In this study we investigated the prevalence and characteristics of seizures and epilepsy in an adult 22q11.2DS population. Methods: The medical records of 202 adult patients with 22q11.2DS were retrospectively reviewed for documentation of seizures, electroencephalography (EEG) reports, and magnetic resonance imaging (MRI) findings. Epilepsy status was assigned in accordance with 2010 International League Against Epilepsy Classification. Results: Of 202 patients, 32 (15.8%) had a documented history of seizure. Of these 32, 23 (71.8%) had acute symptomatic seizures, usually associated with hypocalcemia and/ or antipsychotic or antidepressant use. Nine patients (9/32, 28%; 9/202, 4%) met diagnostic criteria for epilepsy. Two patients had genetic generalized epilepsy; two patients had focal seizures of unknown etiology; two had epilepsy due to malformations of cortical development; in two the epilepsy was due to acquired structural changes; and in one patient the epilepsy could not be further classified. Significance: Similarly to children, the prevalence of epilepsy and acute symptomatic seizures in adults with 22q11.2DS is higher than in the general population. Hypocalcemia continues to be a risk factor for adults, but differently from kids, the main cause of seizures in adults with 22q11.2DS is exposure to antipsychotics and antidepressants. Further prospective studies are warranted to investigate how 22q11.2 microdeletion leads to an overall decreased seizure threshold.
and is caused by a 3-Mb hemizygous microdeletion on the long arm of chromosome 22, resulting in the loss of 46 protein-coding genes (Online Mendelian Inheritance in Man [OMIM] #188400). 2 Patients with 22q11.2DS can present with variable phenotypes, affecting multiple organs and tissues. Classic features include congenital heart defect (CHD), palatal anomalies, and hypocalcemia/hypoparathyroidism. 3, 4 Increasingly, neuropsychiatric manifestations are recognized in 22q11.2DS. These include developmental delay and intellectual disability, psychiatric illness such as schizophrenia, and early onset Parkinson's disease. [5] [6] [7] Other neuropsychiatric manifestations, however, remain poorly characterized. In particular, there is a dearth of research concerning the prevalence and etiology of seizures in adults with 22q11.2DS. The lack of information may be due to the poor survival into adulthood. 4 There is increasing evidence that children with 22q11.2DS are at higher risk for both provoked and unprovoked seizures relative to the general population. 4, 8, 9 In two large pediatric samples of 22q11.2DS, the prevalence of genetic generalized epilepsy (previously called idiopathic generalized epilepsy) was reported as 2.2% and 8.3%, and epilepsy of all types has been cited as high as 6.9% and 15.2%, respectively; 8, 9 In the general population, estimated prevalence of epilepsy in children up to age 17 is 10.2 per 1,000. 10 By contrast, few studies have systematically examined seizures in adults with 22q11.2DS. In a questionnairebased study, Ryan et al. reported that 21% of adults with 22q11.2DS had a history of seizures (not clear if restricted to childhood). 4 It is important to note, however, that the types of seizures were not studied and it was not possible to differentiate between provoked and unprovoked, single, or recurrent seizures in that study. In addition, as it was a questionnaire-based study, it is impossible to know whether pseudoseizures and paroxysmal movement disorders might have been misdiagnosed as seizures.
The current study aimed to quantify the prevalence of both provoked and unprovoked seizures in an adult population of patients with 22q11.2DS. In addition, we sought to characterize this population in terms of seizure type, age at onset, investigational findings, as well as the presence of risk factors for provoked seizures.
Methods
The medical records of 202 adult patients with a documented 22q11.2 deletion were reviewed retrospectively for evidence of seizure activity. Inclusion criteria included (1) a confirmed 22q11.2 microdeletion without evidence of other pathogenic copy number variations (CNVs) on genomewide microarray, (2) a physician-documented history of one or more seizures, and (3) reports of electroencephalography (EEG) and/or magnetic resonance imaging (MRI). This study was approved by the UHN and CAMH Research Ethics Boards and all patients or their caregivers provided written informed consent according to the Declaration of Helsinki.
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EEG reports were evaluated for evidence of interictal focal or generalized epileptiform discharges (IEDs), as well as for evidence of focal or background slowing. MRI reports were evaluated for any structural abnormalities associated with epilepsy, including congenital malformations of cortical development, hippocampal sclerosis, atrophy, malrotation, or areas suggestive of traumatic brain injury. Clinical variables of interest included gender, age, age at onset of seizure, seizure type, and antiepileptic drugs (AEDs) used. Seizures were classified according to the 2010 International League Against Epilepsy classification proposal: generalized tonic-clonic seizure (GTCS), (1) focal motor seizure, (2) focal dyscognitive seizure, and (3) absence seizure. 12 Focal seizures were additionally classified according to whether patients experienced evolution to bilateral convulsive movements (FOEBCM). Potential precipitating events common to this population, such as hypocalcemia, fever, and psychotropic drugs use, were noted. In patients who experienced their first seizure while taking an antipsychotic medication, age at diagnosis of psychosis, antipsychotic/antidepressant history, and medication changes within 3 months preceding seizure were also reviewed. Epilepsy was defined as two or more unprovoked seizures.
Results

Clinical features
Of 202 patients with 22q11.2DS, 52 were investigated with EEG and/or MRI for events suspicious for seizures. Two patients with isolated postoperative seizures in childhood (after cardiovascular surgery associated with stroke) but not since then, were excluded. A confirmed history of seizures was identified in 32 patients (32/202, 15 • Epilepsy is more common in adults with 22q11.2DS than in the general population of adults
• Acute symptomatic seizures are more common than epilepsy in adults with 22q11.2 DS
• Acute symptomatic seizures due to antipsychotics are much more frequent in patients with 22q11.2 DS than in the general population electrophysiology findings compatible with genetic generalized epilepsy (GGE) (patients 25 and 32), and two patients with focal seizures of unknown etiology (patients 7 and 21). The most common type of seizure was GTCS (n = 23). Other types of seizure included FOEBCM (n = 7), focal motor seizure (n = 1), and absence seizure (n = 1). Some patients had notes of "myoclonic seizures." However, upon careful chart and EEG review it was clear that these patients developed myoclonus only after the onset of an antipsychotic medication. Furthermore, there was no electrographic evidence of myoclonic seizures in any of these patients, and the myoclonus was nonepileptic. Two patients had developed status epilepticus (2/32, 6.3%). Individual clinical features and seizure history for all 32 patients are reported in Table 1 .
Nine of the patients (9/32, 28.1%; 9/202, 4.4%) in our sample met diagnostic criteria for epilepsy (recurrent, unprovoked seizures). Among the nine patients with a diagnosis of epilepsy, two had GGE, two had focal seizures of unknown etiology, four had epilepsy due to structural-metabolic causes (malformations of cortical development [MCD] in two and acquired brain injury in two) and one had epilepsy that could not be further classified (unknown epilepsy). EEG studies were obtained in 30 patients (30/32, 93.8%). In 19 patients, prolonged continuous EEG recordings lasting between 3 and 7 days were obtained. Another five patients had more than two routine and/or sleepdeprived EEG studies. Eleven patients had focal interictal epileptiform discharges (IEDs) and six had generalized IEDs. Of note, focal IEDs have been described previously in patients with metabolic or drug-induced seizures. [13] [14] [15] In addition, there were abnormal findings in 22 of the 28 patients who underwent MRI. In four patients these structural abnormalities could be associated with seizures: interhemispheric cyst with colpocephaly (n = 1), polymicrogyria (n = 1), periventricular and white matter nodular heterotopia (n = 1), and gliosis (likely related to previous trauma) on the temporal-parietal gray matter (n = 1) (Fig. 1) .
Regarding risk factors for provoked seizures, 21 patients (21/32, 65.6%) had a diagnosis of hypoparathyroidism and hypocalcemia, according to physician report and laboratory values. All 21 patients were treated for hypocalcemia; however, it is not possible to know which patients were indeed adherent to their treatment. Six patients (6/32, 18.7%) had seizures associated with documented hypocalcemia, although three of them were also on psychotropic drugs (PsyDs), and one of them had a clinical history and EEG findings compatible with an underlying GGE. Thus, two patients had seizures exclusively due to documented hypocalcemia (2/32, 6.2%).
Twenty-one patients (21/32, 65.6%) were taking PsyDs during one or more seizures. Three from those 21 patients also had concomitant hypocalcemia during one or more seizures. Exactly half of our sample (16/32, 50%) had their first seizure while starting or increasing the dose of a PsyDs. As would be expected, these patients were significantly older at age of first seizure relative to those who were not taking antipsychotics (p = 0.0007, unpaired t-test). Four (25%) of these 16 patients had only one seizure; clozapine (n = 8), chlorpromazine (n = 2), clomipramine (n = 2), risperidone (n = 2), and loxapine (n = 1) were the drugs used in these patients. One patient (1/16, 6.3%) developed neuroleptic malignant syndrome (NMS) with GTCS and focal-onset seizures on a combination of haloperidol and flupentixol. Discussion 22q11.2DS is a complex syndrome with variable phenotypic expression. Previous studies have suggested that acute symptomatic seizures (those associated with a precipitant factor such as hypoglycemia, fever, etc.) and repeated unprovoked seizures (epilepsy) are more common in children with 22q11.2DS relative to the general pediatric population. 8, 9 However, no studies have carefully looked at the presence of provoked seizures and epilepsy in the adult population with 22q11.2DS. The current study found that in a sample of 202 adults with 22q11.2DS, 15.8% of patients had a history of seizures and 4.4% of them met diagnostic criteria for epilepsy (only 0.99% had genetic generalized epilepsy). The large majority of our adult population (11.3% of all patients with 22q11.2DS and 71.8% of all patients with seizures) had acute symptomatic (or provoked) seizures. In the general population, the incidence of acute symptomatic seizures is 29-39 per 100,000 per year. 16 In adults with 22q11.2DS, the epilepsy subtypes are not significantly different from those seen in the pediatric cohorts: The current study showed GGE and focal seizures of unknown etiology in four patients (12.5% of patients presenting with seizures and 1% of the total 22q11.2DS population), structural epilepsy caused by malformations of cortical development, trauma, or stroke in another 4 (12.5%; 1%) and unclassified epilepsy in 1 (3.1%; 0.4%). Kao et al. 8 identified numbers similar to ours in their pediatric population (mean age 7.2 years): GGE and focal seizures of unknown etiology in 8 (2.2% of the total population studied), structural causes in 8 (2.2% of the total patients with 22q11.2DS), and unclassified in 8 (2.2% of the total). Kim et al.
9 studied a population of median age 6.6 years, and identified genetic epilepsy (not further divided into generalized and focal) in 12 (8.2%) of their pediatric patients with 22q11.2DS. These authors classified as structural causes for epilepsy polymicrogyria (n = 3), calcifications (n = 2), and stroke (n = 1), but they also included white matter signal changes (n = 2), and cerebral atrophy (n = 3). 9 It is interesting to note that these authors did not comment on provoked seizures; therefore, one might wonder if their higher number of patients with genetic epilepsy does not include patients with repeated acute symptomatic seizures. Overall, genetic epilepsy is more common in the 
PsyDs, antipsychotic drugs; GGE, genetic generalized epilepsy.
a These patients had one or more uncomplicated febrile seizures that stopped before the age of 6 years.
b Myoclonus appeared after starting antipsychotic medications and EEG did not show any correlation, that is, nonepileptic myoclonus.
Epilepsia, 58 (6) pediatric and adult 22q11.2DS patient population compared to the general population. However, genetic epilepsy is more common in children than in adults with this microdeletion. This might be expected, since many sub-syndromes of genetic epilepsy manifest seizures mainly in childhood.
Regarding provoked seizures, the triggering factors are different in the adult, compared to the pediatric 22q11.2DS patient population. In children, common triggers are hypocalcemia, fever, and stroke (often associated with surgical correction of congenital heart defects). 8 In adults, most provoked seizures were associated with the use of antipsychotics, antidepressants, although a history of hypocalcemia (whether treated or not) was also common.
Hypocalcemia, related to dysfunction of the parathyroid glands, is recognized as one of the cardinal features of 22q11.2DS. 17 In a large European cohort, Ryan et al. reported that 70% of patients had hypocalcemia and that 39% presented with seizures. 4 In the current study, about 66% of patients had received a diagnosis of hypoparathyroidism. Hypocalcemia was identified as the sole and primary cause of seizure in two patients, but low calcium levels were also documented in one patient with GGE and in three patients taking antipsychotics/antidepressants around the time of seizure. Therefore, we can estimate the seizure occurrence in our population from 9.5% (2/21) to 28.5% (6/ 21) of patients with hypocalcemia. In neonates, one study has found a significant overlap between neonatal seizures and hypocalcemia in patients with 22q11.2DS. Seven (77.8%) of nine patients who presented with neonatal seizures also had documented hypocalcemia 18 ; these data reinforce the differences between triggering factors for seizures in the adult and pediatric 22q11.2DS patient population.
PsyDs are common in the treatment of adult patients with 22q11.2DS. Up to 50% of adults with 22q11.2DS have some form of psychiatric problems; in our cohort, 119 patients have been treated with PsyDs, and 21 were taking PsyDs during one or more seizures. Thus, 17.6% of 22q11.2DS patients exposed to PsyDs have developed seizures. In comparison with the general population, our data show that the lower seizure threshold is not merely due to PsyD use (17.6% vs. 1.6%). 19 There is a well-established association between schizophrenia and 22q11.2DS. 20 The deletion is found in up to one of every 100 individuals with schizophrenia, representing the most common molecular subtype of schizophrenia to date. [20] [21] [22] Consistent with this finding, most of the patients with schizophrenia in the 22q11.2DS sample studied were taking antipsychotics when they had seizures. Sixteen patients (50% of the patients with seizures) experienced their first seizure while taking an antipsychotic. The antipsychotic most commonly associated with seizure was clozapine. In the general population, clozapine is associated with an increased seizure risk of 1.3%. 19, 23 Other antipsychotics associated with seizure in our study included phenothiazines, risperidone, and haloperidol. In addition, two patients experienced seizures during initiation of the tricyclic antidepressant (TCA) clomipramine. Among antidepressants, clomipramine is recognized to carry the highest risk of seizure, with 1.66% of patients in the general population reporting seizures at doses exceeding 250 mg/day. 19 The mechanism leading to high rates of epilepsy and seizures in patients with 22q11.2DS is not well understood. These patients have a higher incidence of GGE, but also focal seizures of unknown etiology. 8, 9, 24 Patients with 22q11.2DS also have a high incidence of structural abnormalities associated with focal epilepsy such as polymicrogyria (PMG), 25 periventricular nodular heterotopia, 26 and hippocampal atrophy or malrotation. 27, 28 Although 22q11.2 DS has been associated previously with increased risk of epilepsy, this microdeletion also confers a lower seizure threshold in those patients without GGE, focal seizures of unknown etiology, or MCDs. This is demonstrated by the very high occurrence of acute symptomatic seizures (71%) seen in this adult population. The mechanisms behind the lower seizure threshold in 22q11.2 microdeletion are not completely understood. Through traditional methods of sequencing, no single gene in the region of the hemizygous deletion has been associated with the seizure phenotype. One possible mechanism is gene (or genes) dosage imbalance caused by the hemizygous deletion at 22q11.2. Abnormal gene dosage in other regions of the genome have been associated with neurodevelopmental disorders, imbalance of neuronal excitation/inhibition, as well as pharmacologic response to psychotropic drugs. [29] [30] [31] [32] [33] The main limitations of the current investigation are the partly retrospective design and unavoidable restrictions of available data. The frequency of seizures in our cohort, especially nonconvulsive seizures, may be underestimated. In addition, establishing seizure semiology retrospectively often relied on patient report and collateral history. Although most patients had prolonged 3-7 day continuous EEG recordings, this was not possible in all patients. Finally, four patients were claustrophobic and could not tolerate an MRI. In conclusion, this study demonstrated that in an adult population with 22q11.2 DS acute symptomatic seizures (caused by hypocalcemia and/or psychotropic drugs) are much more common than genetic or structural epilepsy (71% vs. 29%). This finding should alert clinicians to the heightened risk of seizures not only in children, but also in adults with 22q11.2 DS, especially those with psychiatric disorders in need of psychotropic medications. Another important conclusion of this study is that the 22q11.2 microdeletion may lead to an overall lower seizure threshold. This is associated with acute symptomatic seizures in a disproportionately high amount of patients with low or normal calcium levels and/or those exposed to antipsychotics.
